Tag: FDA-approved lymphoma therapies 2025

Home / FDA-approved lymphoma therapies 2025

Categories

Acalabrutinib with bendamustine and rituximab is approved by the USFDA for previously untreated mantle cell lymphoma

On January 16, 2025, the Food and Drug Administration granted conventional approval to acalabrutinib (Calquence, AstraZeneca) in combination with bendamustine and rituximab for adults with previously ...
fda-approved-lymphoma-therapies-2025

Scan the code